Name: Prostaglandin E2 (PGE2)
Brand: Selleck Chemicals
SKU: S3003
Rating: 5 (29 reviews)

Aller à

Contrôle qualité (Quality Control)

Lot : Pureté: >97.00%

Cité dans Nature Medicine pour sa qualité supérieure
COA
Fiche technique
SDS

Cité dans Nature Medicine pour sa qualité supérieure
COA
Fiche technique
SDS

Cité dans Nature Medicine pour sa qualité supérieure
COA
NMR
Fiche technique
SDS

Cité dans Nature Medicine pour sa qualité supérieure
COA
NMR
Fiche technique
SDS

Cité dans Nature Medicine pour sa qualité supérieure
COA
NMR
Fiche technique
SDS

97.00

Cibles apparentées	Adrenergic Receptor Estrogen/progestogen Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor THR
Autre PGES Inhibiteurs	Yakuchinone A

Culture cellulaire, traitement et concentration de travail
(Cell Culture, Treatment & Working Concentration)

Lignées cellulaires	Type d'essai	Concentration	Temps d'incubation	Description de l'activité	PMID
HeLa	Function assay			TP_TRANSPORTER: uptake in PGT-expressing HeLa cells, Km = 0.094 μM.	7754369
HeLa	Function assay			TP_TRANSPORTER: uptake in PGT-expressing HeLa cells, K1/2 = 0.1 μM.	8787677
S2	Function assay			TP_TRANSPORTER: uptake in OCT2-expressing S2 cells, Km = 0.0289 μM.	11907186
S2	Function assay			TP_TRANSPORTER: uptake in OAT4-expressing S2 cells, Km = 0.154 μM.	11907186
S2	Function assay			TP_TRANSPORTER: uptake in OAT3-expressing S2 cells, Km = 0.345 μM.	11907186
S2	Function assay			TP_TRANSPORTER: uptake in OCT1-expressing S2 cells, Km = 0.657 μM.	11907186
S2	Function assay			TP_TRANSPORTER: uptake in OAT2-expressing S2 cells, Km = 0.713 μM.	11907186
S2	Function assay			TP_TRANSPORTER: uptake in OAT1-expressing S2 cells, Km = 0.97 μM.	11907186
HEK293	Function assay			Inhibitory activity against human EP4 receptor expressed in HEK293 ebna cells, IC50 = 0.0007 μM.	12643927
HEK293	Function assay			EP4 agonist potency utilizing a stable clone of pSV40-EP4 transfected into HEK293 cells expressing EP4 receptor, EC50 = 0.003 μM.	12643927
Sf9	Function assay			TP_TRANSPORTER: uptake (vesicle) in membrane vesicles from MRP4-expressing Sf9 cells, Km = 3.4 μM.	12835412
HEK293	Function assay			Displacement of [3H]PGE2 from human EP3 receptor expressed in HEK293 cells, Ki = 0.00033 μM.	17531488
HEK293	Function assay			Displacement of [3H]PGE2 from human EP4 receptor expressed in HEK293 cells, Ki = 0.00079 μM.	17531488
HEK293	Function assay			Displacement of [3H]PGE2 from human EP2 receptor expressed in HEK293 cells, Ki = 0.0049 μM.	17531488
HEK293	Function assay			Displacement of [3H]PGE2 from human EP1 receptor expressed in HEK293 cells, Ki = 0.0091 μM.	17531488
HEK293	Function assay			Agonist activity against rat EP2 receptor expressed in HEK293 cells assessed as stimulation of cAMP release, EC50 = 0.0002 μM.	19250823
HEK293	Function assay			Agonist activity against rat EP4 receptor expressed in HEK293 cells assessed as stimulation of cAMP release, EC50 = 0.0007 μM.	19250823
HEK293	Function assay			Inhibition of rat EP4 receptor expressed in HEK293 cells, IC50 = 0.0021 μM.	19250823
HEK293	Function assay			Inhibition of rat EP2 receptor expressed in HEK293 cells, IC50 = 0.0052 μM.	19250823
CHO	Function assay		60 mins	Displacement of [3H]-PGE2 from mouse EP4 receptor expressed in CHO cells after 60 mins by liquid scintillation counting, Ki = 0.0031 μM.	22119471
CHO	Function assay		60 mins	Displacement of [3H]-PGE2 from mouse EP3 receptor expressed in CHO cells after 60 mins by liquid scintillation counting, Ki = 0.005 μM.	22119471
CHO	Function assay		20 mins	Displacement of [3H]-PGE2 from mouse EP1 receptor expressed in CHO cells after 20 mins by liquid scintillation counting, Ki = 0.006 μM.	22119471
CHO	Function assay		60 mins	Displacement of [3H]-PGE2 from mouse EP2 receptor expressed in CHO cells after 60 mins by liquid scintillation counting, Ki = 0.022 μM.	22119471
CHO	Function assay		60 mins	Displacement of [3H]-PGE2 from mouse EP4 receptor expressed in CHO cells after 60 mins by scintillation counting, Ki = 0.0031 μM.	22386979
CHO	Function assay		60 mins	Displacement of [3H]-PGE2 from mouse EP3 receptor expressed in CHO cells after 60 mins by scintillation counting, Ki = 0.005 μM.	22386979
CHO	Function assay		60 mins	Displacement of [3H]-PGE2 from mouse EP1 receptor expressed in CHO cells after 60 mins by scintillation counting, Ki = 0.006 μM.	22386979
CHO	Function assay		60 mins	Displacement of [3H]-PGE2 from mouse EP2 receptor expressed in CHO cells after 60 mins by scintillation counting, Ki = 0.022 μM.	22386979
CHEM1	Function assay		2 hrs	Displacement of [3H]PGE2 from human recombinant prostanoid EP4 receptor in CHEM1 cells after 2 hrs, Ki = 0.00045 μM.	23403082
CHEM1	Function assay		2 hrs	Displacement of [3H]PGE2 from human recombinant prostanoid EP4 receptor in CHEM1 cells after 2 hrs, IC50 = 0.0011 μM.	23403082
CHO	Function assay	100 nM		Activity at recombinant EP1 receptor (unknown origin) expressed in CHO cells co-expressing Gq protein at 100 nM by electrical cell substrate impedance sensing system	25701254
CHO	Function assay	100 nM		Activity at recombinant EP4 receptor (unknown origin) expressed in CHO cells co-expressing Gs protein at 100 nM by electrical cell substrate impedance sensing system	25701254
CHO	Function assay	100 nM		Activity at recombinant EP3 receptor (unknown origin) expressed in CHO cells co-expressing Gi protein at 100 nM by electrical cell substrate impedance sensing system	25701254
CHO	Function assay		30 mins	Agonist activity at human EP2 receptor expressed in CHO cells assessed as increase in intracellular cAMP level after 30 mins by HTRF method, EC50 = 0.0019 μM.	26985320
CHO	Function assay			Agonist activity at human EP3 receptor expressed in CHO cells assessed as increase in intracellular calcium level by fluorescence based analysis, EC50 = 0.0025 μM.	26985320
CHO	Function assay			Agonist activity at human EP1 receptor expressed in CHO cells assessed as increase in intracellular calcium level by fluorescence based analysis, EC50 = 0.0037 μM.	26985320
CHO	Function assay		30 mins	Agonist activity at human EP4 receptor expressed in CHO cells assessed as increase in intracellular cAMP level after 30 mins by HTRF method, EC50 = 0.0075 μM.	26985320
Chem1	Function assay			Agonist activity at human FP receptor expressed in human Chem1 cells assessed as increase in intracellular calcium level by fluorescence based analysis, EC50 = 0.25 μM.	26985320
HEK293	Function assay		90 mins	Agonist activity at PK2-tagged human EP2 receptor expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin recruitment incubated for 90 mins by beta-galactosidase reporter gene assay, EC50 = 0.346 μM.	26985320
CHO	Function assay		30 mins	Agonist activity at human IP receptor expressed in CHO cells assessed as increase in intracellular cAMP level after 30 mins by HTRF method, EC50 = 0.347 μM.	26985320
HEK293	Function assay			Displacement of [3H]PGE2 from human recombinant prostanoid EP2 receptor expressed in HEK293 cells, IC50 = 0.0026 μM.	26988801
HEK293	Function assay		120 mins	Displacement of [3H]PGE2 from human recombinant EP4 receptor expressed in HEK293 cells measured after 120 mins by scintillation counting method, IC50 = 0.00055 μM.	27876250
HEK293	Function assay		120 mins	Displacement of [3H]PGE2 from human recombinant EP2 receptor expressed in HEK293 cells measured after 120 mins by scintillation counting method, IC50 = 0.0026 μM.	27876250
Cliquez pour voir plus de données expérimentales sur la lignée cellulaire

Informations chimiques, stockage et stabilité (Chemical Information, Storage & Stability)

Poids moléculaire	352.47	Formule	C₂₀H₃₂O₅	Stockage (À compter de la date de réception)	3 ans-20°Cpoudre
N° CAS	363-24-6	Télécharger le SDF		Stockage des solutions mères	Les solutions sont instables. Préparer des solutions fraîches ou acheter des formats petits et préemballés. Reconditionner dès réception.
Synonymes	Dinoprostone			Smiles	CCCCCC(C=CC1C(CC(=O)C1CC=CCCCC(=O)O)O)O

Solubilité (Solubility)

In vitro
Lot:

DMSO : 70 mg/mL (198.59 mM)
(Le DMSO contaminé par l'humidité peut réduire la solubilité. Utiliser du DMSO frais et anhydre.)

Ethanol : 70 mg/mL

Water : 2.5 mg/mL

Calculateur de molarité

Masse	Concentration	Volume	Poids moléculaire
=	×	×

Calculateur de dilution Calculateur de poids moléculaire

In vivo Lot:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validé par les laboratoires Selleck. Si vous avez besoin d'ajustements à cette formulation, contactez notre équipe commerciale pour des tests personnalisés.	3.500mg/ml (9.93mM)	Taking the 1 mL working solution as an example, add 50 μL of 70 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

Calculateur de formulation in vivo (Solution claire)

Étape 1 : Saisir les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant l'expérience)

Dosage : mg/kg Poids moyen des animaux : g Volume de dosage par animal :μL Nombre d'animaux :

Étape 2 : Saisir la formulation in vivo (Ceci est seulement le calculateur, pas la formulation. Veuillez nous contacter d'abord s'il n'y a pas de formulation in vivo dans la section Solubilité.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Résultats du calcul :

Concentration de travail : mg/ml;

Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter d'abord si la concentration dépasse la solubilité du DMSO du lot de médicament. )

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouterμL PEG300, mélanger et clarifier, puis ajouterμL Tween 80, mélanger et clarifier, puis ajouter μL ddH₂O, mélanger et clarifier.

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouter μL Huile de maïs, mélanger et clarifier.

Note : 1. Veuillez vous assurer que le liquide est clair avant d'ajouter le solvant suivant.
2. Assurez-vous d'ajouter le(s) solvant(s) dans l'ordre. Vous devez vous assurer que la solution obtenue, lors de l'ajout précédent, est une solution claire avant de procéder à l'ajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie chaud peuvent être utilisées pour faciliter la dissolution.

Mécanisme d'action (Mechanism of Action)

In vitro	Prostaglandin E2 agit via les récepteurs EP4 sur les ostéoclastes pendant la progression de l'OA et de la douleur liée à l'OA.
In vivo	Prostaglandin E2 (0,3 μg/k, i.p.) réduit significativement le nombre de macrophages péritonéaux subissant la phagocytose des microsphères de méthacrylate chez les rats.
Références	[1] https://pubmed.ncbi.nlm.nih.gov/6804558/

Informations sur l'essai clinique (Clinical Trial Information)

(données du https://clinicaltrials.gov, mis à jour le 2024-05-22)

Numéro NCT	Recrutement	Conditions	Promoteur/Collaborateurs	Date de début	Phases
NCT06129604	Recruiting	Colorectal Carcinoma (CRC)\|Endometrial Carcinoma (EC)	University of Oklahoma	April 3 2024	Phase 2
NCT06307678	Completed	Periapical; Infection	Ataturk University	July 7 2023	Not Applicable
NCT06190132	Completed	Uremic Pruritus in Hemodialysis Patients	Ain Shams University	April 1 2023	Not Applicable

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Prostaglandin E2 (PGE2) Prostaglandin E Receptor agonist

Structure chimique

Poids moléculaire: 352.47

Contrôle qualité (Quality Control)

Culture cellulaire, traitement et concentration de travail
(Cell Culture, Treatment & Working Concentration)

Informations chimiques, stockage et stabilité (Chemical Information, Storage & Stability)

Solubilité (Solubility)

Calculateur de molarité

Calculateur de formulation in vivo (Solution claire)

Mécanisme d'action (Mechanism of Action)

Informations sur l'essai clinique (Clinical Trial Information)

Prostaglandin E2 (PGE2) Prostaglandin E Receptor agonist

Structure chimique

Poids moléculaire: 352.47

Contrôle qualité (Quality Control)

Culture cellulaire, traitement et concentration de travail (Cell Culture, Treatment & Working Concentration)

Informations chimiques, stockage et stabilité (Chemical Information, Storage & Stability)

Solubilité (Solubility)

Calculateur de molarité

Calculateur de formulation in vivo (Solution claire)

Mécanisme d'action (Mechanism of Action)

Informations sur l'essai clinique (Clinical Trial Information)

Culture cellulaire, traitement et concentration de travail
(Cell Culture, Treatment & Working Concentration)